Injection technique is identical for both medications: subcutaneous injection into the abdomen, thigh, or upper arm
Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, has emerged as the commercial powerhouse, with the oral version launching in January 2026 following December 2025 FDA approval [3]
For example, GLP-1R agonists were able to improve glucose metabolism function through the GLP-1R/SIRT1/GLUT4 pathway in an AD model (Figure 2), suggesting that GLP-1R may be a key factor linking these two diseases
This bundle is designed to change that
7 Initiating and monitoring If adding a DPP-4 inhibitor to sulfonylurea, meglitinide or insulin therapy, consider whether a dose reduction of the sulfonylurea/meglitinide/insulin is needed to reduce hypoglycaemia risk
10.2337/dc14-1142 80